# reload+after+2024-01-20 02:43:33.906951
address1§13631 Progress Blvd.
address2§Suite 400
city§Alachua
state§FL
zip§32615
country§United States
phone§386 462 6800
fax§386 462 6801
website§https://www.axogeninc.com
industry§Medical Devices
sector§Healthcare
longBusinessSummary§AxoGen, Inc., together with its subsidiaries, develops and markets technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.
fullTimeEmployees§394
companyOfficers§[{'maxAge': 1, 'name': 'Ms. Karen  Zaderej', 'age': 61, 'title': 'Chairman, President & CEO', 'yearBorn': 1962, 'fiscalYear': 2022, 'totalPay': 852183, 'exercisedValue': 150313, 'unexercisedValue': 230510}, {'maxAge': 1, 'name': 'Mr. Michael  Donovan', 'age': 58, 'title': 'Vice President of Operations', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 406018, 'exercisedValue': 30750, 'unexercisedValue': 46300}, {'maxAge': 1, 'name': 'Mr. Angelo G. Scopelianos Ph.D.', 'age': 68, 'title': 'Chief Research & Development Officer', 'yearBorn': 1955, 'fiscalYear': 2022, 'totalPay': 540912, 'exercisedValue': 0, 'unexercisedValue': 20550}, {'maxAge': 1, 'name': 'Mr. Nir  Naor C.F.A., CPA, L.L.M., M.B.A.', 'age': 49, 'title': 'Chief Financial Officer', 'yearBorn': 1974, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ed  Joyce', 'title': 'Director of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Marc A. Began', 'age': 55, 'title': 'Executive VP, General Counsel & Chief Compliance Officer', 'yearBorn': 1968, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Doris  Quackenbush', 'title': 'Vice President of Sales', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jens Schroeder Kemp', 'title': 'Chief Marketing Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Erick  DeVinney', 'age': 47, 'title': 'Vice President of Peripheral Nerve Science and Clinical Innovation', 'yearBorn': 1976, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§1
boardRisk§4
compensationRisk§6
shareHolderRightsRisk§1
overallRisk§2
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
exDividendDate§1264550400
payoutRatio§0.0
beta§0.95
priceToSalesTrailing12Months§2.4171634
currency§USD
dateShortInterest§1702598400
forwardEps§-0.04
exchange§NCM
quoteType§EQUITY
shortName§AxoGen, Inc.
longName§AxoGen, Inc.
firstTradeDateEpochUtc§535213800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§7bcdc4f6-2582-3323-ab9e-9d3722f90de9
gmtOffSetMilliseconds§-18000000
targetHighPrice§17.0
targetLowPrice§9.0
targetMeanPrice§12.17
targetMedianPrice§11.5
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§6
quickRatio§2.096
grossMargins§0.8153
ebitdaMargins§-0.13326
trailingPegRatio§None
